AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01589497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
Study NCT01589497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants were administered one 400 mg tablet orally once a day.
Study NCT01740050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Description: One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
Study NCT01740050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Study NCT01740050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAGB
Study NCT02112487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: 10 mg once daily
Study NCT04538183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5000
Description: WO 5000
Study NCT04538183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5001
Description: WO 5001
Study NCT01582152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI287
Description: Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Study NCT01582152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
Study NCT03188835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
Study NCT03188835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/MRS
Description: Visceral and cervico-thoracic MRI and MRS acquisition.
Study NCT03188835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram (EMG)
Description: Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
Study NCT03188835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DXA
Description: Lean mass will be determined by dual-energy X-ray absorptiometry
Study NCT03188835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indirect calorimetry
Description: VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
Study NCT02180867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02180867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02180867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT02180867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO
Study NCT02180867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT02180867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02180867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03815331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex®
Description: medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
Study NCT03815331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aveed
Description: Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
Study NCT04012775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Humulin® NPH
Description: 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study NCT03047629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENT-01
Description: Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
Study NCT03047629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing with a placebo
Study NCT03259412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil Capsule
Study NCT04012775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Rinsulin® NPH
Description: 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study NCT03259412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil capsule manufactured to mimic fish oil capsule
Study NCT03267667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiography and cardiac MRI
Description: imaging of right ventricle by both modalities to assess right ventricle function accurately
Study NCT01257568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rejuvenate Modular Hip
Description: Rejuvenate Modular Hip
Study NCT04216784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Patient will receive furosemide intravenously
Study NCT04216784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Human
Description: Patient will receive albumin (25%) 12.5 gm intravenously
Study NCT02019108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive walking program with toe-out gait modification
Description: Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
Study NCT02019108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive walking program
Description: At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
Study NCT01801748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral wheat challenge
Study NCT01657890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral
Study NCT01349361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daylight mediated photodynamic therapy
Study NCT01576419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG201 tablet
Description: One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
Study NCT01576419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex capsule
Description: One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
Study NCT02182206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study NCT01887015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)
Study NCT01887015 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)
Study NCT04030754 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: amniotic membrane
Description: amniotic membrane is a biological dressing
Study NCT04030754 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: duoderm dressing
Description: duoderm dressing is a synthetic dressing
Study NCT05883358 — intervention group
Intervention type: DRUG
Intervention: Clonidine, Buprenorphine
Description: Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
Study NCT04049253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study NCT04049253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study NCT01380873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001
Study NCT01380873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701
Study NCT01380873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807
Study NCT00799604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
Study NCT00481000 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Dialectical Cognitive Therapy
Description: Dialectical Behavior Therapy in Combination with Traumafocused CBT
Study NCT01264588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical calcium glycerophosphate lotion
Description: 2g once daily for 6 weeks (post-op day 3 thru 42)
Study NCT02389348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: Single oral doses of DSM265
Study NCT04042376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
Study NCT03987646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-staged vestibular fresh socket therapy
Description: a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
Study NCT05063006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.
Description: Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
Study NCT05063006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.
Description: During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
Study NCT02794363 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous platelet rich plasma
Description: 5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
Study NCT01888536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limaprost
Study NCT01888536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limaprost
Study NCT01888536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study NCT01888536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Pregabalin)
Description: mimic Pregabalin 75mg capsule
Study NCT01888536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Limaprost)
Description: mimic Limaprost tablet
Study NCT02039219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
Study NCT02039219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Obeticholic Acid (OCA)
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
Study NCT04098367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVITY
Description: Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
Study NCT04098367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYMFONY
Description: Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
Study NCT04098367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LARA
Description: Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
Study NCT04098367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract removal by routine small incision surgery
Study NCT04198467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
Study NCT04198467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
Study NCT04275167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Description: Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
Study NCT03395600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B1S5
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
Study NCT03395600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B125S5
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
Study NCT03744429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will be provided with meals that follow a Mediterranean meal plan.
Study NCT03036462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: i.v. iron administration
Study NCT03036462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. NaCl administration
Study NCT04098367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract removal by routine small incision surgery
Study NCT03395600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B1S10
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
Study NCT01406106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol esters
Description: The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
Study NCT01406106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plant stanol esters
Description: The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
Study NCT03163563 — intervention group
Intervention type: DEVICE
Intervention: Easywarm
Description: Warming blanket
Study NCT03163563 — intervention group
Intervention type: DEVICE
Intervention: BairHugger
Description: Patient warming mattress with continuous warm air.
Study NCT01412606 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scratching
Description: scratching endometrium on day 21-26 of a spontaneous menstrual cycle
Study NCT01412606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: scratching endometrium on day 21-26 of a spontaneous menstrual cycle
Study NCT04350619 — intervention group
Intervention type: OTHER
Intervention: Genetic screening. No therapeutic intervention
Description: Genetic screening using NGS technique. No therapeutic intervention
Study NCT03927651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.